Clearmind Medicine secures $10 million financing agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
September 19, 2025 8:20 AM EDTVancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (Clearmind or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities purchase agreements (the SPAs) with institutional investors (the Holders). Pursuant to the SPAs, the Company may issue and sell, from time to time, convertible promissory notes (the Notes) in an aggregate principal amount of up to $10,000,000. Upon the execution of the SPAs (the First Initial Closing), the Company issued and sold to the Holders... More
